<DOC>
	<DOC>NCT02823574</DOC>
	<brief_summary>A study in patients with metastatic or recurrent squamous cell cancer of the head and neck to evaluate the effectiveness of Nivolumab plus Ipilumumab vs. Nivolumab alone (CheckMate 714)</brief_summary>
	<brief_title>Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Confirmed squamous cell head and neck cancer Widespread (metastatic) disease, or returned after previous treatment (recurrent) Tumor sample must be available for analysis of PDL1 (Programmed deathligand 1) and HPV [Human Papilloma Virus (oropharynx only)] Performance status ECOG 01 (Eastern Cooperative Oncology Group) Previous treatment for metastatic or recurrent disease Cancer arising from one of the following primary sites: paranasal sinus, nasopharynx, salivary gland, skin Any nonsquamous subtype Active autoimmune disease Positive test for hepatitis B, C or HIV (Human Immunodeficiency Virus) virus Previous treatment with checkpoint inhibitor drugs Active CNS metastases or carcinomatous meningitis Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>